Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANB-002
- Development stage
- Unknown
- Lead developer
- Biocad
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
ANB-002 is an investigational gene therapy developed for the treatment of hemophilia B. It consists of a recombinant adeno-associated virus (rAAV) vector designed to deliver a functional copy of the human coagulation factor IX (FIX) gene to the liver. By enabling the endogenous production of Factor IX, ANB-002 aims to restore blood clotting capability and reduce or eliminate the need for exogenous factor replacement therapy in patients with hemophilia B. The therapy is currently being evaluated in clinical trials in China, sponsored by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences.
- Other names
- rAAV-hFIX
02
Targets
F9 (Coagulation Factor IX)
Beyond the preview
Go deeper on ANB-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANB-002.